Kemwell Announces Successful FDA Inspection at Bangalore Facility

Author(s)Pharmaceutical Technology Editors

The company announced that no Form 483 was observed at the company’s facility in Bangalore, India.

On Feb. 20, 2017, Kemwell Biopharma announced that its oral solids manufacturing facility in Bangalore, India successfully completed an FDA inspection. The inspection confirmed that the site is compliant with principles of current good manufacturing practices and no Form 483 observations were issued. In a statement, the company said the audit was triggered by an abbreviated new drug application filed for a customer. This facility is part of Kemwell’s pharmaceutical business for which Kemwell has signed a purchase agreement with Recipharm.

Source: Kemwell

Articles in this issue

over 8 years ago

Article

Viewpoint: No Clear Path for Pharma or Outsourcing

over 8 years ago

Article

Standards Set Excipient GMPs, But Collaboration is Needed

over 8 years ago

Article

Mass Spectrometry Measures Up to Biologics Drug Analytical Challenges

over 8 years ago

Article

Monitoring Supply Chain Risk on a Limited Budget

over 8 years ago

Article

Evaluating E&L Studies for Single-Use Systems

over 8 years ago

Article

PfizerCentreOne Expands Fill/Finish Services in Michigan

over 8 years ago

Article

Metrohm USA Announces Winner of Young Chemist Award

over 8 years ago

Article

Novasep Opens New Bioconjugation Unit in France

over 8 years ago

Article

Abzena Signs Antibody Manufacturing Development Agreement with UCL

over 8 years ago

Article

Recipharm Completes Kemwell Acquisition

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!